James Hardie delivers a stark contrast this year with net income sinking 75% to USD104 million despite stronger sales momentum. Profit was USD424 million in the prior year so the drop is sharp.
Management points to the AZEK acquisition costs, restructuring charges and asbestos-related compensation as the key drag. A tax settlement with the Australian Taxation Office in the second quarter also weighs on the bottom line.
Behind the profit hit, the top line looks strong with group net sales jumping 25% year-on-year to USD4.83 billion. Operating income does not keep pace, sliding 32% to USD447 million as costs rise.
Adjusted EBITDA improves 17% to USD1.26 billion, showing the underlying business is expanding. Guidance for FY27 targets adjusted EBITDA of USD1.45 billion to USD1.50 billion and net sales between USD5.25 billion and USD5.41 billion.
Housing conditions and regional splits shape performance. The company highlights ongoing inflation and affordability pressures that pull housing activity down by a mid-to-high single-digit % over the year.
Net income is further squeezed by asbestos expenses layered on top of AZEK integration costs and the ATO settlement. Sales growth is anchored in Australia and New Zealand where core fibre cement products see solid demand, while Europe and Germany in particular remains a tough market with only gradual recovery expected.
Management signals caution about the near-term backdrop, noting the operating environment remains uncertain and a broad housing rebound is not baked into its plans. Confidence instead leans on execution of AZEK synergies, a revamped go-to-market model and manufacturing cost actions taken in FY26.
The company focuses on disciplined capital allocation as it balances heavy one-off costs with growth targets. Investors now have to weigh robust revenue and EBITDA trends against the drag from legacy liabilities and acquisition spending.
